News Medical

Spiriva Respimat (with dose indicator)

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiriva Respimat contains the active ingredient tiotropium. Spiriva ...
Yahoo

New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype1,2,3

New analyses show improved lung function * and asthma symptom control and reduced asthma exacerbations for patients with allergic asthma 1,2,3 These analyses evaluated the safety and efficacy of ...
Monthly Prescribing Reference

Spiriva Respimat Gains Indication and New Dosage Strength

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...
FiercePharma

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...
Monthly Prescribing Reference

Spiriva Respimat Gets Expanded Approval for Pediatric Asthma Maintenance

This approval was based on efficacy and safety data from the Phase 2 and Phase 3 UniTinA-asthma clinical development program. The Food and Drug Administration (FDA) has approved Spiriva Respimat ...
FierceBiotech

FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD

RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...
Healio

FDA to review new drug application for Spiriva Respimat for asthma

Please provide your email address to receive an email when new articles are posted on . Boehringer Ingelheim Pharmaceuticals announced that the FDA has agreed to review its new drug application for ...
FiercePharma

FDA Approves Boehringer Ingelheim's SPIRIVA RESPIMAT for the Maintenance Treatment of Asthma in Adults and Adolescents

RIDGEFIELD, Conn., September 16, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, ...
Business Wire

Asthma: new indication for Spiriva ® (tiotropium) Respimat ®* in the EU may offer millions of adults a significant advance in asthma care

INGELHEIM, Germany--(BUSINESS WIRE)--For media outside the US, the UK & Canada only Boehringer Ingelheim today announced that the indication for Spiriva ® (tiotropium) Respimat ®* in asthma has been ...
The Financial

Adding SPIRIVA Respimat Effective for Uncontrolled Asthma – Regardless of Allergy Subtype

The FINANCIAL — Boehringer Ingelheim on March 8 announced the presentation of new post-hoc analyses that show the addition of SPIRIVA (tiotropium) Respimat to other asthma maintenance therapies helps ...
Business Wire

New advance in COPD maintenance treatment, Spiolto ® Respimat ®, approved in first European countries

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced regulatory authority approvals for Spiolto ® Respimat ® (tiotropium/olodaterol) in first ...